We are live on ! Find out more
RNTX

Rein Therapeutics
RNTX

37 hedge funds and large institutions have $8.34M invested in Rein Therapeutics in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.01% less ownership

Funds ownership: 1.78% → 1.77% (-0.01%)

12% less funds holding

Funds holding: 42 → 37 (-5)

49% less capital invested

Capital invested by funds: $16.5M → $8.34M (-$8.16M)

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

Holders
37
Holders Change
-5
Holders Change %
-11.9%
% of All Funds
0.62%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
2
Increased
10
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
+$65.2K
2
TSS
Two Sigma Securities
New York
+$34.5K
3
Renaissance Technologies
Renaissance Technologies
New York
+$26K
4
Jane Street
Jane Street
New York
+$18.8K
5
State Street
State Street
Massachusetts
+$14.2K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$87.4K
2
B
Bailard
California
-$66K
3
JSMC
Jess S. Morgan & Co
California
-$51K
4
Citigroup
Citigroup
New York
-$15K
5
KWM
Keebeck Wealth Management
Illinois
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
1
Alerce Investment Management
Illinois
$4.32M – – –
BI
2
BVF Inc
California
$1.37M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$804K – – –
IC
4
Ikarian Capital
Texas
$752K -$4.48K -488 -0.3%
William Blair & Company
5
William Blair & Company
Illinois
$299K +$65.2K +7,096 +14%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$226K +$2.42K +264 +0.6%
KL
7
KCK Ltd
Bermuda
$168K – – –
BFM
8
Boothbay Fund Management
New York
$72K – – –
TCA
9
Taconic Capital Advisors
New York
$35K – – –
Envestnet Asset Management
10
Envestnet Asset Management
Illinois
$31K +$147 +16 +0.3%
Northern Trust
11
Northern Trust
Illinois
$30K -$6.47K -704 -11%
Renaissance Technologies
12
Renaissance Technologies
New York
$30K +$26K +2,835 +97%
GPFA
13
Game Plan Financial Advisors
Ohio
$27K +$4.59K +500 +11%
State Street
14
State Street
Massachusetts
$27K +$14.2K +1,544 +43%
CG
15
Colony Group
Massachusetts
$23K – – –
Jane Street
16
Jane Street
New York
$20K +$18.8K +2,049 +118%
TSS
17
Two Sigma Securities
New York
$20K +$34.5K +3,754 New
Osaic Holdings
18
Osaic Holdings
Arizona
$11K +$735 +80 +4%
UWM
19
Urban Wealth Management
California
$10K +$17.1K +1,866 New
TRCT
20
Tower Research Capital (TRC)
New York
$9K +$10.9K +1,188 +239%
JWA
21
JFS Wealth Advisors
Pennsylvania
$8K – – –
KAS
22
Kestra Advisory Services
Texas
$8K – – –
Morgan Stanley
23
Morgan Stanley
New York
$7K -$2.03K -221 -15%
US Bancorp
24
US Bancorp
Minnesota
$7K – – –
VF
25
Virtu Financial
New York
$5K -$340 -37 -3%
1
2

RNTX Hedge Fund Activity: Q2 2022 in Review

37 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2022, worth a combined $8.34M — down 49% from $16.5M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of RNTX and 2 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 10 added.

The largest buyer was William Blair & Company, adding an estimated $65.2K. The largest seller was BlackRock, cutting an estimated $87.4K.

  • 37 institutional investors held Rein Therapeutics (RNTX) as of Q2 2022, down from 42 in Q1 2022.
  • Funds reported $8.34M of Rein Therapeutics stock for Q2 2022, down 49% quarter-over-quarter.
  • 2 funds opened new Rein Therapeutics positions in Q2 2022 and 7 closed out, a net change of -5 holders.
  • The largest Rein Therapeutics buyer in Q2 2022 was William Blair & Company, an estimated $65.2K added.
  • The largest Rein Therapeutics seller in Q2 2022 was BlackRock, an estimated $87.4K sold.

Based on aggregated 13F filings for Q2 2022.